News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ProNAi Therapeutics, Inc. Names Polymun Scientific Immunbiologische Forschung GmbH as Preferred Manufacturer of PNT2258 DNAi(R)-based Cancer Therapeutic


6/14/2007 12:57:03 PM

KALAMAZOO, Mich. & VIENNA, Austria--(BUSINESS WIRE)--ProNAi Therapeutics, Inc., a biopharmaceutical company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi®), today announced that it has signed a supply agreement with Polymun Scientific GmbH, an Austrian contract biopharmaceutical developer, to manufacture the company’s PNT2258 DNAi®-based cancer therapeutic.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES